Cancer Patients' blood thinner mystery solved?
NCT ID NCT05819736
First seen Jun 04, 2026 · Last updated Jun 08, 2026 · Updated 2 times
Summary
This study measured how two common blood thinners (rivaroxaban and apixaban) behave in 193 adults with active cancer who also had blood clots or atrial fibrillation. Researchers aimed to understand factors like age, weight, and kidney function that affect drug levels. The goal was to gather real-world data to guide safer use of these medications in cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTICOAGULANTS AND THROMBOTIC DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre d'Investigation Clinique Hôpital Pitié-Salpêtrière
Paris, 75013, France
Conditions
Explore the condition pages connected to this study.